Oxamusplatin: a cytotoxic Pt(ii) complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer
- 17 January 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 49 (8) , 2547-2558
Abstract
Pt(II) drugs and nitrogen mustards show severe side effects, poor tumour selectivity and face growing resistance by cancer cells due to sequestration by thiol-containing molecules (viz. glutathione (GSH) and copper ATPases like ATP7A/7B). ATP7A and ATP7B-sequestered Pt(II) complexes show dose inefficacy and resistance. The incorporation of bulky ligands and chelating leaving groups may prevent deactivation by thiols. In this work, we have synthesised four new Pt(II) complexes (3–6) of two carrier ligands, bis(2-hydroxyethyl)pyridylmethylamine (L1) and bis(2-chloroethyl)pyridylmethylamine (L2) with oxalato and cyclobutanedicarboxylato leaving groups. Among these four new complexes, the Pt(II) complex of L2 with the oxalato leaving group (5, termed “oxamusplatin”) is cytotoxic. Oxamusplatin is more resistant than cisplatin or oxaliplatin towards hydrolysis, thiol binding and sequestration by ATP7B. It targets cellular DNA and is capable of disrupting the microtubule network in the cytoskeleton. Oxamusplatin demonstrates better selectivity than oxaliplatin towards cancerous cells. It is ca. 4–10 times more cytotoxic towards metastatic prostate carcinoma (DU-145, IC50 = 21 ± 1 μM) and ca. 10–24 times more cytotoxic towards breast adenocarcinoma (MCF-7, IC50 = 8.1 ± 0.8 μM) compared to the three noncancerous cells investigated.Keywords
Funding Information
- Anusandhan National Research Foundation (EMR/2017/002324, ECR/2015/000220)
- Wellcome Trust DBT India Alliance (IA/I/16/1/502369)
This publication has 54 references indexed in Scilit:
- Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profileProceedings of the National Academy of Sciences, 2012
- Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side EffectsCancers, 2011
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapyMolecular Cancer, 2007
- A Third Mode of DNA Binding: Phosphate Clamps by a Polynuclear Platinum ComplexJournal of the American Chemical Society, 2006
- Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer CellsClinical Cancer Research, 2004
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Copper‐transporting P‐type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRPInternational Journal of Cancer, 2002
- Integrating Oxaliplatin into the Management of Colorectal CancerThe Oncologist, 2001